Development of stability indicating liquid chromatographic method for estimation of novel anti‐diabetic drug Evogliptin
SEPARATION SCIENCE PLUS · 2023-12 · 6 (12)
DOI: 10.1002/sscp.202300082 ↗Kurz gefasst
Fachartikel in der Zeitschrift SEPARATION SCIENCE PLUS, online erschienen am 19.09.2023. Verfasst von Deepanti Gajjar und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Evogliptin (EVG) is prescribed in the treatment of type 2 diabetes. An accurate and precise high‐performance liquid chromatographic method along with forced degradation studies and design of experiments has been developed for the estimation of EVG. Agilent C 18 Column (250 × 4.6 mm, 5 μm particle size) was used as the stationary phase and methanol: 0.05% Orthophosphoric acid in water (51: 49% V/V) was used as the mobile phase. The method was linear in the concentration range of 5–30 μg/ml with a correlation coefficient (r 2 ) of 0.9996. The proposed method was validated with respect to linearity, accuracy, precision, and robustness as per the International Conference on Harmonization Q2 (R1) guideline. A forced degradation study was performed to find out the intrinsic stability of the molecules. The degradation products were well resolved from the drug peak and did not interfere with the analysis. The method was successfully applied for the analysis of EVG.
Zitieren
APA
Gajjar, D., & Shah, D. S. (2023). Development of stability indicating liquid chromatographic method for estimation of novel anti‐diabetic drug Evogliptin. SEPARATION SCIENCE PLUS, 6(12). https://doi.org/10.1002/sscp.202300082
Vancouver
Gajjar D, Shah DS. Development of stability indicating liquid chromatographic method for estimation of novel anti‐diabetic drug Evogliptin. SEPARATION SCIENCE PLUS. 2023;6(12). doi:10.1002/sscp.202300082
BibTeX
@article{Gajjar2023,
author = {Gajjar, Deepanti and Shah, Dimalkumar S.},
title = {Development of stability indicating liquid chromatographic method for estimation of novel anti‐diabetic drug Evogliptin},
journal = {SEPARATION SCIENCE PLUS},
year = {2023},
volume = {6},
number = {12},
doi = {10.1002/sscp.202300082}
}
EUVIMED